This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify a lead compound series toward development of potential therapeutic agents to treat heart, lung, blood, and sleep (HLBS) diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical optimization and development of therapeutic agents.

This specific Catalyze Product Definition initiative will provide the early stage translational support needed for the activities required to develop a lead compound series to identify potential therapeutics to treat HLBS diseases and disorders. Following successful completion of the program, it is expected that the lead compound series will be poised to move forward for preclinical testing (optimization, safety, efficacy) with additional support from NIH and/or other federal and private programs. For projects that are at an earlier stage (target identification and validation), a companion initiative is available (RFA-HL-23-011). Through Catalyze, the small molecule and biologics initiatives have companion initiatives that support development of devices, diagnostics and tools (RFA-HL-23-013 and RFA-HL-23-014), and an initiative to support the development of enabling technologies and transformative platforms for HLBS (RFA-HL-23-010). See website for additional information.

Deadlines:

• Letter of Intent: 30 days prior to the application due date
• Application Due Dates: March 21, 2022; July 21, 2022; Nov 21, 2022; Feb 21, 2023; July 21, 2023; Nov 21, 2023; Feb 21, 2024; July 22, 2024; Nov 21, 2024
• AIDS Application Due Dates: April 18, 2022; Aug 18, 2022; Dec 21, 2022; April 18, 2023; Aug 18, 2023; Dec 21, 2023; April 18, 2024; Aug 19, 2024; Dec 20, 2024

RFA-HL-23-012 Expiration Date: December 21, 2024